The stock of Sera Prognostics Inc (SERA) has seen a 48.13% increase in the past week, with a 68.90% gain in the past month, and a -21.75% decrease in the past quarter. The volatility ratio for the week is 33.57%, and the volatility levels for the past 30 days are at 17.30% for SERA. The simple moving average for the past 20 days is 43.97% for SERA’s stock, with a -46.54% simple moving average for the past 200 days.
Is It Worth Investing in Sera Prognostics Inc (NASDAQ: SERA) Right Now?
The 36-month beta value for SERA is at 1.25. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SERA is 23.26M, and currently, shorts hold a 3.76% of that float. The average trading volume for SERA on July 01, 2025 was 347.70K shares.
SERA) stock’s latest price update
The stock of Sera Prognostics Inc (NASDAQ: SERA) has decreased by -32.27 when compared to last closing price of 4.09. Despite this, the company has experienced a 48.13% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2025-06-30 that Sera Prognostics’ PreTRM test shows strong clinical utility in reducing neonatal morbidity and NICU admissions, outperforming standard cervical length screening. The company is well-capitalized with $114 million in cash, sufficient to fund commercialization efforts into 2028, despite current losses. Key growth drivers include commercial reimbursement, Medicaid coverage, and inclusion in clinical guidelines, targeting a large and underserved preterm birth market.
Analysts’ Opinion of SERA
Many brokerage firms have already submitted their reports for SERA stocks, with Citigroup repeating the rating for SERA by listing it as a “Neutral.” The predicted price for SERA in the upcoming period, according to Citigroup is $4 based on the research report published on March 30, 2022 of the previous year 2022.
Oppenheimer, on the other hand, stated in their research note that they expect to see SERA reach a price target of $19. The rating they have provided for SERA stocks is “Outperform” according to the report published on November 19th, 2021.
SERA Trading at 21.88% from the 50-Day Moving Average
After a stumble in the market that brought SERA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.66% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SERA starting from Jackson Benjamin, who sale 965 shares at the price of $1.48 back on Jun 10 ’25. After this action, Jackson Benjamin now owns 134,198 shares of Sera Prognostics Inc, valued at $1,428 using the latest closing price.
Boniface John J., the Chief Scientific Officer of Sera Prognostics Inc, sale 1,439 shares at $1.48 during a trade that took place back on Jun 10 ’25, which means that Boniface John J. is holding 167,982 shares at $2,130 based on the most recent closing price.
Stock Fundamentals for SERA
Current profitability levels for the company are sitting at:
- -319.9 for the present operating margin
- 0.09 for the gross margin
The net margin for Sera Prognostics Inc stands at -286.85. The total capital return value is set at -0.39. Equity return is now at value -41.36, with -31.71 for asset returns.
Based on Sera Prognostics Inc (SERA), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -330.07. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -2452.53.
Currently, EBITDA for the company is -32.04 million with net debt to EBITDA at 0.15. When we switch over and look at the enterprise to sales, we see a ratio of 839.34. The receivables turnover for the company is 4.6for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.02.
Conclusion
In conclusion, Sera Prognostics Inc (SERA) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
